Alpha-Synuclein Ligands for PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for neurodegenerative diseases like Parkinson's are inadequate for early detection and monitoring, particularly due to the lack of effective tools for identifying aggregations of misfolded proteins such as α-synuclein.
Innovation Solution
Development of compounds that act as α-synuclein ligands, including radiolabeled analogs, which can be used for diagnosing and monitoring synucleinopathies through positron emission tomography (PET) imaging, allowing for the quantification of α-synuclein protein aggregation in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for neurodegenerative diseases, then diagnosis can be made based on clinical symptoms, but early detection and monitoring of α-synuclein aggregation is not possible
Solution Approach 1:
The patent develops radioligands with specific molecular structures (Formulas I-a, I-b, II, III) that bind to α-synuclein aggregates with high affinity. By changing the chemical parameters of the ligand molecules (substituents R1-R18, heteroatoms A1-A18), the invention achieves selective binding to pathological aggregates while maintaining solubility and appropriate pharmacokinetic properties, enabling early detection through PET imaging
Solution Approach 2:
The invention replaces clinical symptom-based diagnosis (subjective mechanical assessment) with molecular imaging using radioligands. The radiolabeled compounds (e.g., [18F]TZ61-44, [11C]TZ55-107) allow direct visualization and quantification of α-synuclein aggregates in the brain through PET scanners, substituting indirect clinical observation with direct molecular detection
2Reliability
If radiolabeled α-synuclein ligands are developed for PET imaging, then early detection and monitoring capability is achieved, but compound complexity and synthesis requirements increase
Solution Approach 1:
The radioligand molecules are designed as segmented structures with distinct functional regions: aromatic cores (quinoline, pyridine rings), linker chains (alkylene, alkoxy groups), and radiolabel attachment points. This segmentation allows independent optimization of each region for binding affinity, pharmacokinetics, and radiolabeling efficiency, reducing overall complexity while maintaining high diagnostic reliability
Solution Approach 2:
The patent uses intermediary radiolabeling precursors that can be easily converted to final radiolabeled compounds. These intermediaries (e.g., compounds with tosylate, mesylate, or halide leaving groups) facilitate efficient incorporation of short-lived radionuclides like 18F or 11C, simplifying the overall synthesis process while ensuring high specific activity and diagnostic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide accurate early detection and monitoring of α-synuclein aggregation, improving diagnostic accuracy and enabling the assessment of disease progression and therapeutic efficacy for Parkinson's disease and other synucleinopathies.
Implementation Method 1
radiolabeled analogs of these compounds that are useful for diagnosing or monitoring a synucleinopathy in a subject
Implementation Method 2
quantification of α-synuclein protein aggregation in the brain
Data Source
AI summary
The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).